Aim: In our previous studies we found that cyclopentenane prostaglandin A1 (PGA1) had neuroprotective effects in a rodent ischemic model. In the present study we aimed to investigate the inhibitory effect of PGA1 on platelet function. Method: The rate of aggregation of human platelets was measured by using turbidimetry. The rate of adhesion of platelets to cultured endothelial cells was determined by using [ 3 H]-adenine labeled platelets. 5-Hydroxytryptamine release from platelets was measured with O-phthaldialdehyde fluorospectrophotometry. The levels of TXB 2 , a stable metabolite of TXA 2 , were determined by radioimmunoassay. Alternations in platelet morphology were observed using an electron microscope, and the intraplatelet free calcium concentrations were measured with Fluo-3/AM FCM assay. Results: PGA1 significantly inhibited thrombin-, collagen-and ADP-induced aggregation and adhesion of platelets. The morphological changes of platelets induced by thrombin were blocked by PGA1. PGA1 inhibited the release of 5-hydroxytyptamine from dense granules and the synthesis of TXA 2 . Conclusion: PGA1 inhibits the activation of platelets probably through blocking increases in intracellular calcium concentration and TXA 2 synthesis.
Introduction
Prostaglandins are derived from arachidonic acid liberated from the cell membrane. They are produced in a variety of tissues and mediate an array of physiologic and pathologic processes, including regulation of respiratory, vascular, intestinal and inflammatory activities [1] . Cyclopentenone prostaglandins (cycPG), including the A and J series, are formed from the enzyme-induced dehydration of prostaglandin E and D. They have some unique biological activities that are different from those of classic prostaglandins, such as inducing cell differentiation [2] , anti-tumor [3] [4] [5] and anti-virus activities [6, 7] . Prostaglandin A1 (PGA1) has many pharmacological actions, including inhibiting tumor growth, inflammation and viral replication [8−11] . We have reported previously that PGA1 inhibits excitotoxin-induced apoptosis of striatal neurons in vivo and rotenone-induced apoptosis of cultured SH-SY5Y cells [12, 13] . In a recent study, we found that PGA1 significantly reduced infarction volume in rodent models of focal cerebral ischemia [14, 15] . PGA1 influences several cellular signaling pathways, including activation of peroxisome proliferator-activated receptor γ (PPARγ) [16] , inhibition of nuclear factor-kappaB (NF-κB) [11, 17] , and induction of heat shock proteins [18, 19] . The molecular signaling pathways involved in its neuroprotection, however, remain to be determined.
The activation and aggregation of platelets play an important role in the pathological process of cerebral ischemia through interactions with endothelial cells and formation of thrombosis [20, 21] . It has been shown that drugs inhibiting platelet function, including aspirin, could be beneficial in preventing ischemic attack. The effects of some prostaglandins on platelets have been reported [22, 23] . However, information about the effects of PGA1 on platelets is incomplete and inconsistent; therefore, the aim of the present study was to determine if PGA1 had an inhibitory effect on the functions of human platelets. We found that PGA1 inhibited platelet aggregation, release of TXB 2 and platelet adhesion to endothelial cells. These actions could contribute to its neuroprotective effects in rodent models of stroke.
Materials and methods
Drugs and reagents PGA1, thrombin, Fluo-3 acetoxymethyl ester (Fluo-3 AM), sulfinpyrazone, and A23187 were purchased from Sigma (St Louis, MO, USA); adenosine 5' diphosphate (ADP), N-(2-hydroxyethylpiperazine)-NV-(2-ethanesulfonic acid) (HEPES), and ethylene glycol bi-β-aminoethylether)-N,N,NV-tetraacetic acid (EGTA) were purchased from Shanghai Sangon Bioengineering and Technology Service (Shanghai, China). Collagen was purchased from the Jiangsu Institute of Hematology (Suzhou, China).
Platelet preparations Venous blood was obtained from healthy donors with no drug history for at least 14 d, and immediately mixed with a one-ninth volume of citrate acid Platelet aggregation assay Aggregation of platelets was evaluated by using an MPG-3E aggregometer (Shanghai Silong Medical Instrument Factory, Shanghai, China) according to the manufacturer's instructions. PRP was first incubated with ethanol (with a final concentration of 0.8%, as a vehicle control), or different concentrations of PGA1 at 37 °C for 5 min. Platelet aggregation was triggered by adding 20 µL of ADP, collagen and thrombin to 200 µL of PRP to achieve final concentrations of 40 µmol/L, 40 µg/mL and 0.25 U/mL, respectively.
Platelet adhesion assay Platelets were washed and treated as described earlier. Human umbilical endothelial cells were cultured in 96-well plates and grown to cover the entire surface of wells. Endothelial cells were pre-treated with Triton X-100 (0.5%) before use. Thrombin-stimulated platelet suspension was added to each well and incubated for 30 min. The adherent platelets were stained with Rose Bengal (0.25%) at 37 °C and then dissolved in absolute ethanol 30 min later. The number of adherent platelets was determined by measuring absorption using a wavelength of 570 nm.
Assay of 5-hydroxytryptamine release from platelets Levels of 5-hydroxytryptamine (5-HT) released from platelets were determined by using O-phthaldialdehyde (OPT) fluorospectrophotometry as described elsewhere [2] . Briefly, platelets were obtained and washed as described earlier, and different concentrations of PGA1 (20- Evaluation of ultrastructure of platelets The effect of PGA1 on ultrastructural changes of platelets induced by thrombin was examined with an electron microscope. Washed platelets were pretreated with PGA1 (20-80 µmol/L), then thrombin (0.25 U/mL) was added to activate platelets 5 min later. Platelets were then fixed with 4% (w/v) glutaraldehyde after a 5 min incubation with thrombin, stained with osmium tetroxide, dehydrated, and embedded in Araldite. Ultrathin sections were examined with a Philips CM-120 electron microscope.
TXB 2 assay Platelets were obtained as described earlier. Washed platelets were prepared and pre-incubated with PGA1 (20-80 µmol/L) or vehicle (final concentration=0.8% ethanol) for 5 min. Then thrombin was added and the reaction was terminated (500 µL of ice-cooled stop solution containing 50 mmol/L EDTA; 2 mmol/L indomethacin, 130 mmol/L NaCl) 5 min later. Samples were then centrifuged at 500×g for 10 min at 4 °C. Supernatants were used for determination of the levels of TXB 2 with radioimmunoassay (TXB 2 Radioimmunoassay kit, Jiangsu Institute of Hematology).
Determination of cytosolic free calcium The intracellular [Ca 2+ ] was determined using Fluo-3 AM, essentially as described elsewhere [1] . Briefly, PRP was incubated with 8 µmol/L Fluo-3 AM for 30 min at 37 °C; the dyed platelets were spun down and gently re-suspended at a concentration of approximately 1×10 8 cells/mL in the HEPES-buffered solution containing 140 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl 2 , 10 mmol/L glucose and 20 mmol/L HEPES, supplemented with 100 mmol/L sulfinpyrazone to prevent the cellular efflux of Fluo-3 acid. The external [Ca 2+ ] was adjusted to 1 mmol/L and the fluorescence was measured with flow cytometer using excitation and emission wavelengths of 488 nm and 526 nm, respectively. Calibration of the ratio of fluorescence signals into pseudo fluorescence was performed using 1 µmol/L A23187 to obtain the maximal ratio, followed by 5 mmol/L EGTA to obtain the minimal ratio. Platelets were incubated with PGA1 (20-80 µmol/L) at 37 °C for 5 min in HEPES-buffered solutions before the addition of thrombin. The full response was obtained in solutions containing 1 mmol/L CaCl 2 . Calcium concentration was estimated as follows: F p =(F-F min )/(F max -F max ). To clarify whether the rise in intracellular calcium is derived from intracellular reservoirs or the entry of extracellular Ca 2+ , platelets were stimulated in a Ca 2+ -free solution, and calcium concentration was estimated as described earlier.
Statistical analysis Statistical analyses of the differences between vehicle control and PGA1-treated samples were carried out with an unpaired, two-tailed Student's t-test, and P<0.05 was considered significant. Figure 2 ). PGA1 significantly decreased the release of 5-HT from the dense granules of platelets induced by thrombin (P<0.05; Figure 3) . The lactate dehydrogenase (LDH) assay showed that there was no difference in LDH leakage among groups with and without PGA1 treatment using the same samples for 5-HT assay, excluding the possibility that the increase in 5-HT in supernatant was caused by damage of platelets during preparation (data not shown).
Results

PGA1 inhibited platelet activation
PGA1 inhibited the ultrastructural changes of platelets Stimulated platelets transform from a discoid form to a spiny spherical shape with numerous pseudopodia (shape change); simultaneously, the fibrinogen receptors that mediate aggregation are exposed. We investigated the effects of PGA1 on platelet morphology after thrombin stimulation with an electron microscope. We found that thrombin elicited robust changes in platelet morphology, including formation of numerous pseudopodia and loss of dense granules. Pretreatment with PGA1 almost completely blocked the thrombin-induced shape changes (formation of pseudopodia) and aggregation of human platelets (Figure 4) . PGA1 inhibited TXA 2 synthesis and calcium influx in platelets TXA 2 is a potent activator of platelets. Addition of thrombin to platelets stimulated synthesis of TXB 2 , a stable metabolite of TXA 2 . PGA1 dose-dependently inhibited the production of TXB 2 (P<0.05). The IC 50 of PGA1 on TXB 2 production was 34.1 µmol/L (P<0.05; Figure 5 ). Calcium is a key player in activation of platelets. PGA1 (20-80 µmol/L downregulated the increase in calcium concentration inside the platelets induced by thrombin (P<0.05; Figure 6A ). When calcium was absent in the extracellular solution, we failed to observe an inhibition of calcium increase by PGA1 ( Figure  6B ), suggesting that PGA1 inhibited calcium influx from the extracellular space.
Discussion
Most actions of the cyclopentenone prostaglandins, including PGA2, PGA1, and PGJ2, are not mediated by binding to G-protein-coupled prostanoid receptors, but result from their direct interaction with other cellular target proteins [8] . The pharmacological actions of PGA1 with respect to its anti-inflammatory, anti-neoplastic, and anti-viral activities have been well documented. Recently, our in vivo and in vitro studies suggested that PGA1 has neuroprotective actions [12, 14, 15] , but the mechanisms underlying its neuroprotective effects have not been fully understood.
Platelet aggregation, adhesion to endothelial cells and release of TXA 2 play important roles in the formation of thrombosis. TXA 2 causes constriction of blood vessels, which could further reduce blood flow in the brain. Inhibitors of platelet function are commonly used in therapeutic approaches in the treatment of brain ischemia [24, 25] . Previous studies have found inconsistent results with respect to the effect of PGA1 on platelet aggregation. PGA1 has been reported to have no effect on aggregation of rabbit platelets induced by ADP, or formation of thrombus in rats [26, 27] , or weakly inhibited platelet aggregation at high concentrations [28] . Since platelets from different species commonly respond differently to platelet inhibitors, we thought that human platelets might be sensitive to PGA1. The present studies thus examined the effects of PGA1 on the functions of human platelets. The results showed that PGA1 significantly inhibited thrombin-induced human platelet aggregation, the release of 5-HT, and production of TXA 2 . Similar inhibitory results were obtained with respect to platelet aggregation induced by collagen and ADP with less potency. PGA1 inhibited the thrombin-induced increase in cytosolic [Ca 2+ ]. These actions could be part of mechanisms by which PGA1 inhibits platelet activation. It has been well documented that in almost every step of platelet activation, calcium is required. We found that the inhibitory effect of PGA1 on rises in calcium concentration was not seen in the absence of extracellular calcium, suggesting that PGA1 may inhibit calcium influx. However, additional studies are required to confirm whether PGA1 blocks calcium entry into platelets. In our study of the effect of PGA1 on thrombin-induced 5-HT release and increases in intraplatelet calcium concentration, the medium dose of PGA1 (40 µmol/L) was less effective. The reason for this is unknown at present. Also, the effects of PGA1 on calcium entry into platelets need to be further investigated under other experimental conditions.
In addition to the above-discussed pharmacological actions, PGA1 inhibits IκB-α degradation and NF-κB activation, induces expression of heat shock proteins and activates PPAR-γ. The significance of these pharmacological actions of PGA1 with respect to the ability of PGA1 to inhibit platelets and neuronal injury in ischemia need to be further investigated.
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